Kartik Krishnan
Chief Medical OfficerDr. Kartik Krishnan, M.D. Ph.D. is Chief Medical Officer of Pasithea Therapeutics Corp. from May 1, 2026. He oversees all clinical development and medical strategy as the Company advances PAS-004 through the clinic for the treatment of neurofibromatosis type 1 (NF1) associated plexiform and cutaneous neurofibromas. He was President and Head of Research & Development of OncoNano Medicine Inc. from November 2023 until March 2024 and served as it CEO since March 2024. He is also Director of OncoNano Medicine Inc. Dr. Krishnan has excelled in both R&D and pharmacovigilance at multiple biotechnology and large pharmaceutical companies in roles of increasing responsibility. During his tenure at OncoNano, he has spearheaded the progression of ONM-501, a dual-activating STING agonist, into first in human studies and prioritized the next set of novel pipeline medicines. He was Chief Medical Officer of OncoNano Medicine Inc. from June 2022 to November 2023. He served as Chief Medical Officer at Arcus Biosciences, Inc. since October 2021 until 2022. He served as Senior Vice President of Clinical Development of Arcus Biosciences, Inc. since 2019 until October 2021. He will assume full leadership of the Arcus clinical development program. He joined Arcus in 2019 as Vice President of clinical development and has been responsible for contributing to much of the strategy, design and execution associated with Arcus’s broad array of clinical trials and has assumed increasing responsibilities since December when Grossman began consulting for Gilead while concurrently Acting as CMO at Arcus. He assumed additional leadership responsibilities, both strategic and operational and liaise with his long-time colleague Grossman to ensure seamless interactions across the two companies. Dr. Krishnan earned both his M.D. and Ph.D. in Cellular, Molecular and Biophysical Studies from Columbia University. Dr. Krishnan received his B.A. in History (with Distinction) from the University of Virginia.
Positions
- Company NamePasithea Therapeutics Corp.Stock CodeKTTAPositionChief Medical Officer
